Key result
Targeting β1-adrenoreceptor autoantibodies emerges as a novel heart failure approach awaiting clinical outcomes trials.
Clinical outcomes trials are needed to determine the utility of targeting β1-adrenoreceptor autoantibodies in heart failure.
Not ready for clinical use in heart failure; leaves open efficacy pending outcomes trials.
-AR autoantibodies. However, clinical outcomes trials are needed to assess the clinical utility of this novel approach to treat heart failure.
No takes yet. Share an insight, caveat, or question.
Düngen et al. (2020) studied this question. Targeting β1-adrenoreceptor autoantibodies represents a novel approach to treat heart failure, but clinical outcomes trials are needed to assess its clinical utility.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: